Medical/Pharmaceuticals
Samsung Biologics Issues Its First Annual Sustainability Report
* Consolidation of the company's roadmap to creating an improved business environment * Establishment of an ESG Committee for its continued efforts for environmental performance * Showcases the company's long-term commitment to social responsibility as part of its mission to build a bett...
2021-06-25 09:01
23156
Peijia Medical's Jasper® SS Detachable Coil Receives NMPA Approval for Commercialization
SUZHOU, China, June 24, 2021 /PRNewswire/ -- On June 15, 2021, Jasper® SS—a new detachable coil independently developed by Achieva Medical, subsidiary of Peijia Medical (9996.HK)—was approved by the National Medical Products Administration ("NMPA") for commercialization (registration number GXZZ ...
2021-06-25 00:27
17154
Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE
NANJING, China, June 24, 2021 /PRNewswire/ -- Triastek, Inc. (Triastek), a global leader in 3D printed pharmaceuticals, has completed its Series B financing, raisingUS$ 50 million (RMB 330 million). This round of investment was co-led by Matrix Partners China and CPE, with participation from Shan...
2021-06-24 20:43
3268
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
Highlights: * Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. * Concurrence with Alterity's plan to target early stage MSA patients. * Endorsement on selection ...
2021-06-23 21:21
15502
Over a year into the global pandemic, Samsung Biologics continues to leverage innovative virtual platform for remote audits and regulatory inspections
* Samsung Biologics' Live Virtual Tour (LVT) used in one of the earliest FDA full virtual assessments * Recently hosted EMA for 6 PAIs simultaneously using LVT INCHEON, South Korea ,June 23, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (C...
2021-06-23 19:28
1852
Senhwa Announces IND Submission to India's CDSCO of a Phase II Clinical Study for Silmitasertib as a Potential COVID-19 Treatment
TAIPEI and SAN DIEGO, June 23, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for the treatment of cancer, rare conditions, and novel coronaviruses, today announced that it has submitted an I...
2021-06-23 19:00
1882
Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars
BEIJING and BOSTON, June 22, 2021 /PRNewswire/ -- Biocytogen, an international biotechnology company focused on antibody drug research and development (R&D) using innovative genetically engineered animal models, today announced the successful completion of a new round of financing totaling tens o...
2021-06-23 04:16
1999
Phase III Clinical Trial of BIOKANGTAI COVID-19 Vaccine Initiated in Malaysia
SHENZHEN, China, June 22, 2021 /PRNewswire/ -- On June 21, local time, phase III clinical fieldwork of the Inactivated COVID-19 Vaccine (Vero cells) independently developed and manufactured by Shenzhen Kangtai Biological Products Co., Ltd. was officially initiated inMalaysia, and the first batch ...
2021-06-22 22:32
10114
Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®
SHANGHAI, June 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced dosing of the first patient inEurope in its multinational, multicenter, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira® which is being developed for ...
2021-06-22 13:15
1654
Berry Oncology Partners with Alibaba Health to Create China's Early Cancer Screening Ecosystem
BEIJING, June 21, 2021 /PRNewswire/ -- Berry Oncology Corporation, a member company of Berry Genomics, and Alibaba Health have signed a strategic agreement to jointly build a comprehensive cancer screening and prevention ecosystem based on a strategy that combines internet connectivity, early can...
2021-06-21 21:00
2001
I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board
SHANGHAI and GAITHERSBURG, Md., June 21, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the appointment ofAndrew Zhu, MD, PhD, to the Company's ...
2021-06-21 20:00
7945
TIAN RUIXIANG Holdings Ltd Steps into Healthcare Management Industry
BEIJING, June 21, 2021 /PRNewswire/ -- TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the "Company"), a China-based insurance broker, announced today that the Company plans to explore and expand into healthcare management industry. The Company plans to cooperate with governments, insurance companies,...
2021-06-21 20:00
23438
Duke-NUS and GenScript Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test
PISCATAWAY, N.J. and SINGAPORE, June 21, 2021 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading life sciences research and application service and product provider, and Duke-NUS Medical School, a premier, research intensive medical school, annou...
2021-06-21 19:27
9024
Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL.
NANJING, China, June 20, 2021 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL...
2021-06-20 21:00
3373
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma
BEIJING, June 18, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib atthe 16th International Conf...
2021-06-18 17:12
14289
RBC Expands Global Youth Charity Program - RBC Charity Day for the Kids
* Virtual celebrations held by RBC Capital Markets employees in Canada, U.S., U.K.,France, Germany, Japan, Hong Kong, Australia, Barbados and Bahamas * US$5 million donated to over 50 charities worldwide SYDNEY, June 18, 2021 /PRNewswire/ -- As part of a global charitable initiative called RBC...
2021-06-17 20:00
2386
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 17, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study. This study will eval...
2021-06-17 15:41
14450
InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma
BEIJING, June 16, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its pan-FGFR inhibitor gunagratinib (ICP-192) ...
2021-06-17 11:31
14711
Spark Aligners Does It Again With Market Leading Innovation And New FDA Approval To Give Doctors Greater Control And Flexibility
-- New Features in Release 11 Combined with Expanded Indication for Mixed Dentition to Treat Kids and Teens is a Home Run for Doctors -- BREA, Calif., June 16, 2021 /PRNewswire/ -- Ormco Corporation, a global leader of orthodontic solutions, today announced it has received FDA clearance to tre...
2021-06-16 20:45
2055
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer t...
2021-06-16 13:08
9006
Week's Top Stories
Most Reposted
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
[Picked up by 321 media titles]
2026-04-09 13:00
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
[Picked up by 312 media titles]
2026-04-09 09:00Visa cements global K-pop connection as Worldwide Tour Sponsor for "BTS WORLD TOUR 'ARIRANG'"
[Picked up by 308 media titles]
2026-04-06 10:00
Tata Power Collaborates with Databricks to Build Future-Ready Data and AI Platform to Accelerate Energy Transition
[Picked up by 302 media titles]
2026-04-10 11:13
UTP Advances Across Key Disciplines in QS World University Rankings By Subject 2026 - Petroleum Engineering Among World's Top 10
[Picked up by 300 media titles]
2026-04-06 16:46
Most Read
NYSE Content Update: Starfish Space Adds Over $100 Million in Funding to Boost Growth
2026-04-07 21:06
5951
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
2026-04-09 13:00
5280
NYSE Content Update: HumanX to Ring Remote Bell with 350+ Speakers On Site
2026-04-08 21:12
4937
